지속형 피하 인슐린 주입 시장 : 제품 유형, 인슐린 유형, 기술 유형, 연령층, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Continuous Subcutaneous Insulin Infusion Market is projected to grow by USD 1,640.30 million at a CAGR of 10.42% by 2032.

Continuous Subcutaneous Insulin Infusion (CSII), commonly known as insulin pump therapy, is moving from a specialist diabetes intervention to a core pillar of technology-enabled diabetes management. CSII delivers rapid-acting insulin through programmable basal rates and bolus dosing, helping people with type 1 diabetes and selected insulin-requiring type 2 diabetes populations manage glycemic variability with greater precision than conventional injection schedules.

Market momentum is supported by the rising global diabetes burden, broader use of continuous glucose monitoring (CGM), and clinical demand for automated insulin delivery systems. The World Health Organization reports that the number of people living with diabetes increased from 200 million in 1990 to 830 million in 2022, underscoring the long-term need for scalable, evidence-based insulin delivery solutions. Clinical guidelines increasingly recognize insulin pump therapy and CGM-integrated care as important options for improving time-in-range, reducing hypoglycemia risk, and supporting individualized diabetes treatment.

Transformative Shifts in CSII and Automated Insulin Delivery

The CSII landscape is being reshaped by the convergence of insulin pumps, CGM sensors, mobile applications, and algorithm-driven dosing support. Tubed pumps continue to serve patients needing highly customizable programming, while patch pumps are expanding appeal through discreet wearability and simplified user experience. Interoperable pump platforms are also changing procurement decisions by allowing compatible components to work within broader digital diabetes ecosystems.

Regulatory pathways and payer expectations are shifting toward demonstrable outcomes, usability, cybersecurity, and real-world evidence. Hybrid closed-loop systems, first cleared in the United States in 2016, accelerated the transition from manual pump therapy to automated insulin delivery, making time-in-range, hypoglycemia reduction, infusion set performance, device reliability, and patient-reported burden key competitive indicators.

Cumulative Impact of AI on Insulin Pump Therapy

Artificial intelligence is adding cumulative value across CSII by improving glucose forecasting, pattern recognition, remote monitoring, and clinical decision support. AI-enabled analytics can identify recurring hyperglycemia, nocturnal hypoglycemia risk, missed boluses, and insulin sensitivity changes, helping clinicians personalize pump settings more efficiently while supporting patients between clinic visits.

The most defensible AI opportunity is not fully autonomous care, but safer, explainable augmentation of insulin therapy. Industry leaders must align AI models with regulatory expectations for software as a medical device, protect sensitive health data, validate performance across diverse populations, and maintain transparent human oversight in dosing-related recommendations. As automated insulin delivery expands, AI will be most valuable when it strengthens safety, usability, adherence, and clinically validated personalization rather than replacing clinician judgment.

Key Regional Insights Across CSII Adoption

North America remains a leading CSII adoption region due to mature endocrinology networks, established reimbursement pathways, high CGM penetration, and early regulatory acceptance of automated insulin delivery. The United States is particularly influential because cleared pumps, CGMs, and interoperable systems often set reference points for global commercialization and clinical evidence expectations, while Canada's provincial reimbursement models create structured but variable access to insulin pump therapy.

Europe benefits from strong diabetes care infrastructure, national health systems, and procurement models that increasingly evaluate quality-adjusted outcomes, device usability, safety, and long-term clinical value. Asia-Pacific is expanding as China, Japan, India, South Korea, and Australia improve diabetes technology access, although affordability, specialist availability, diabetes education, and reimbursement depth remain uneven. Latin America shows demand growth in urban private healthcare systems, especially where specialist diabetes care and CGM use are increasing, while public-sector access remains constrained. The Middle East is supported by high diabetes prevalence, premium hospital investment, and national noncommunicable disease strategies, particularly in higher-income Gulf countries. Africa remains earlier stage, with CSII access shaped by insulin affordability, supply continuity, limited reimbursement for advanced diabetes devices, and uneven availability of trained endocrinology teams.

Key Group Insights for CSII Stakeholders

G7 markets anchor global CSII innovation through advanced reimbursement systems, established diabetes technology pathways, clinical trial activity, and early adoption of CGM-integrated pump therapy. The European Union adds scale through harmonized medical device regulation under the Medical Device Regulation framework, while national reimbursement decisions continue to determine patient access, procurement speed, and clinical uptake across member states.

BRICS countries represent long-term adoption potential because of large diabetes populations, expanding middle-class healthcare demand, and growing digital health infrastructure, but pricing, distribution, import dependency, and clinician training are decisive adoption factors. ASEAN markets are heterogeneous, with higher-income and urban centers demonstrating stronger private-sector uptake than lower-income settings where diabetes technology reimbursement is limited. GCC countries benefit from high healthcare spending, diabetes-focused public health strategies, and investment in specialist care, supporting interest in insulin pumps and automated insulin delivery. NATO membership is less directly tied to CSII demand, but overlapping North American and European healthcare, defense-health, and procurement standards reinforce cybersecurity, supply resilience, data protection, and device quality expectations for connected diabetes technologies.

Key Country Insights in CSII Markets

The United States is the most influential CSII country market, supported by advanced pump portfolios, CGM integration, telehealth-enabled endocrinology, established device clearance pathways, and strong patient advocacy. Canada follows with structured provincial reimbursement variation, while Mexico and Brazil show expanding private-market demand alongside public access constraints and uneven specialist availability. The United Kingdom, Germany, France, Italy, and Spain rely on guideline-led diabetes care, health technology assessment, and reimbursement evaluation, though access speed differs by payer, region, and clinical eligibility criteria. Russia faces a more constrained environment due to procurement complexity, reimbursement limitations, and technology supply considerations.

China and India provide substantial long-term adoption opportunities because of their large diabetes populations, but affordability, awareness, reimbursement development, and specialist capacity strongly influence insulin pump uptake. Japan, South Korea, and Australia show stronger readiness for automated insulin delivery because of advanced clinical infrastructure, high digital health maturity, established diabetes care pathways, and reimbursement or subsidy mechanisms for selected diabetes technologies. Across these countries, the strongest CSII adoption conditions occur where CGM access, pump training, endocrinology capacity, patient education, and payer recognition of outcomes such as time-in-range align within routine diabetes care.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize interoperable, patient-centered CSII platforms that integrate pumps, CGMs, dosing algorithms, mobile connectivity, and secure cloud analytics. Competitive advantage will come from reducing training burden, improving infusion set reliability, extending wear time where clinically validated, simplifying onboarding, and demonstrating measurable outcomes such as increased time-in-range, reduced severe hypoglycemia, and lower diabetes management burden.

Manufacturers and healthcare stakeholders should expand real-world evidence programs, localize affordability strategies, and invest in clinician education for pump initiation, data interpretation, and troubleshooting. Partnerships with payers, diabetes clinics, pharmacies, advocacy groups, and digital health providers can accelerate adoption while ensuring cybersecurity, post-market surveillance, software update governance, and equitable access remain central to commercialization. Leaders should also design region-specific pathways that address reimbursement requirements, local clinical guidelines, language needs, supply continuity, and patient support infrastructure.

Research Methodology

This executive assessment applies a triangulated research methodology combining verified secondary sources, regulatory databases, peer-reviewed clinical literature, public health datasets, reimbursement policies, product labeling, medical device clearance records, and diabetes care guidelines. Sources are evaluated for credibility, recency, geographic relevance, methodological transparency, and consistency with established clinical and regulatory evidence.

Insights are strengthened through market mapping across device types, end-user settings, reimbursement environments, regional access conditions, clinical adoption barriers, and technology readiness. Findings are interpreted using evidence-based analysis of clinical utility, regulatory feasibility, adoption barriers, competitive positioning, patient usability, cybersecurity considerations, and long-term demand drivers in CSII and automated insulin delivery. No market sizing, market share, or forecasting assumptions are used in this assessment.

Conclusion

CSII is entering a new phase defined by automation, interoperability, AI-assisted personalization, and outcomes-based access expectations. As diabetes prevalence continues to rise globally, insulin pump therapy is positioned to play a larger role in improving glycemic management, reducing patient burden, and supporting data-driven clinical care across type 1 diabetes and selected insulin-requiring type 2 diabetes populations.

The strongest opportunities will favor organizations that combine clinically validated technology with affordability, cybersecurity, usability, regulatory readiness, and regional access strategies. Stakeholders that can translate innovation into trusted, reimbursable, and scalable diabetes care solutions will be best positioned in the evolving CSII ecosystem.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Continuous Subcutaneous Insulin Infusion Market, by Product Type

• 7.1. Insulin Pumps
  • 7.1.1. Tethered Pumps
  • 7.1.2. Patch pumps
• 7.2. Pump Accessories
  • 7.2.1. Infusion sets
  • 7.2.2. Batteries
  • 7.2.3. Reservoirs
  • 7.2.4. Patches
• 7.3. CSII Software & Digital Platforms
  • 7.3.1. Remote Monitoring App
  • 7.3.2. Data Management & Analytics Platforms
  • 7.3.3. Automated Insulin Delivery

8. Continuous Subcutaneous Insulin Infusion Market, by Insulin Type

• 8.1. Rapid Acting Analog
• 8.2. Regular Insulin
• 8.3. Short Acting

9. Continuous Subcutaneous Insulin Infusion Market, by Technology Type

• 9.1. Conventional Insulin Pumps
• 9.2. Sensor-Augmented Pumps
• 9.3. Advanced Closed-Loop Systems

10. Continuous Subcutaneous Insulin Infusion Market, by Age Group

• 10.1. Adult
• 10.2. Geriatric
• 10.3. Pediatric

11. Continuous Subcutaneous Insulin Infusion Market, by End User

• 11.1. Ambulatory Care
• 11.2. Homecare
• 11.3. Hospitals
• 11.4. Diabetes clinic

12. Continuous Subcutaneous Insulin Infusion Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Continuous Subcutaneous Insulin Infusion Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Continuous Subcutaneous Insulin Infusion Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. B. Braun SE
• 16.2. Baxter International, Inc.
• 16.3. Becton, Dickinson and Company
• 16.4. Bigfoot Biomedical, Inc.
• 16.5. BPL Medical Technologies Private Limited
• 16.6. CeQur SA
• 16.7. F. Hoffmann-La Roche Ltd.
• 16.8. Forbion
• 16.9. Fresenius SE & Co. KGaA
• 16.10. Insulet Corporation
• 16.11. MannKind Corporation
• 16.12. Medtronic PLC
• 16.13. MicroPort Scientific Corporation
• 16.14. Nipro Corporation
• 16.15. Pharmasense AG
• 16.16. Sanofi S.A.
• 16.17. Shinmyung Mediyes CO., LTD.
• 16.18. SOOIL Developments Co., Ltd.
• 16.19. Tandem Diabetes Care, Inc.
• 16.20. Terumo Group
• 16.21. Ypsomed AG